Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. identification of a suitable "back-up" compound for N-tert-butyl isoquine

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1828-1844

  O'Neill, Paul M ^a   Shone, Alison E ^a   Stanford, Deborah ^a   Nixon, Gemma ^a   Asadollahy, Eghbaleh ^a   Park, B Kevin ^a   Maggs, James L ^a   Roberts, Phil ^a   Stocks, Paul A ^a   Biagini, Giancarlo ^b   Bray, Patrick G ^b   Davies, Jill ^b   Berry, Neil ^a   Hall, Charlotte ^b   Rimmer, Karen ^b   Winstanley, Peter A ^a   Hindley, Stephen ^a   Bambal, Ramesh B ^c   Davis, Charles B ^c   Bates, Martin ^d   Gresham, Stephanie L ^d   Brigandi, Richard A ^c   Gomez de las Heras, Federico M ^e   Gargallo, Domingo V ^e   Parapini, Silvia ^f   Vivas, Livia ^g   Lander, Hollie ^g   Taramelli, Donatella ^f   Ward, Stephen A ^b   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GLAXOSMITHKLINE   (Spain)

^f UNIVERSITY OF MILAN   (Italy)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(4 CHLORO 3 DIBUTYLAMINOMETHYLPHENYL)(7 CHLOROQUINOLIN 4 YL)AMINE; (4 CHLORO 3 PYRROLIDIN 1 YLMETHYL PHENYL)(7 CHLOROQUINOLIN 4 YL)AMINE; (7 CHLOROQUINOLIN 4 YL)(3 IMIDAZOL 1 YLMETHYLPHENYL)AMINE; (7 CHLOROQUINOLIN 4 YL)(4 CHLORO 3 IMIDAZOL 1 YLMETHYLPHENYL)AMINE; (7 CHLOROQUINOLIN 4 YL)(4 FLUORO 3 IMIDAZOL 1 YLMETHYLPHENYL)AMINE; 4' FLUORO N TERT BUTYLAMODIAQUINE; 7 CHLORO N [4 CHLORO 3 [(4 ETHYLPIPERAZIN 1 YL)METHYL]PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 CHLORO 3 [(4 METHYLPIPERAZIN 1 YL)METHYL]PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 CHLORO 3 [(PIPERIDIN 1 YL)METHYL]PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 CHLORO 3 [[4 (PYRIDIN 2 YL)PIPERAZIN 1 YL]METHYL]PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 FLUORO 3 (MORPHOLINOMETHYL)PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 FLUORO 3 [(4 METHYLPIPERAZIN 1 YL)METHYL]PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 FLUORO 3 [(PIPERIDIN 1 YL)METHY]PHENYL]QUINOLIN 4 AMINE; 7 CHLORO N [4 FLUORO 3 [(PYRROLIDIN 1 YL)METHYL]PHENYL]QUINOLIN 4 AMINE; [3 (TERT BUTYLAMINOMETHYL) 4 CHLOROPHENYL](7 CHLOROQUINOLIN 4 YL)AMINE; [3 (TERT BUTYLAMINOMETHYL) 4 FLUOROPHENYL](7 CHLORO QUINOLIN 4 YL)AMINE; [3 (TERT BUTYLAMINOMETHYL)PHENYL](7 CHLOROQUINOLIN 4 YL)AMINE; [4 CHLORO 3 (4 ISOPROPYLPIPERAZIN 1 YLMETHYL)PHENYL](7 CHLOROQUINOLIN 4 YL)AMINE; AMODIAQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; N [3 [(DIBUTYLAMINO)METHYL] 4 FLUOROPHENYL] 7 CHLOROQUINOLIN 4 AMINE; N [3 [(DIETHYLAMINO)METHYL] 4 CHLOROPHENYL] 7 CHLOROQUINOLIN 4 AMINE; N [3 [(DIETHYLAMINO)METHYL] 4 FLUOROPHENYL] 7 CHLOROQUINOLIN 4 AMINE; N [3 [(DIPROPYLAMINO)METHYL] 4 CHLOROPHENYL] 7 CHLOROQUINOLIN 4 AMINE; N [3 [(DIPROPYLAMINO)METHYL] 4 FLUOROPHENYL] 7 CHLOROQUINOLIN 4 AMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; GENOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MALE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM YOELII; RAT;

AMINOQUINOLINES; AMODIAQUINE; ANIMALS; ANTIMALARIALS; CELL SURVIVAL; CHLOROQUINE; DOGS; DRUG RESISTANCE; FEMALE; HAPLORHINI; HEPATOCYTES; HUMANS; MALARIA; MALE; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64549138445     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8012757     Document Type: Article

References (56)

1. White, N. J.; Nosten, F.; Looareesuwan, S.; Watkins, W. M.; Marsh, K.; Snow, R. W.; Kokwaro, G.; Ouma, J.; Hien, T. T.; Molyneux, M. E.; Taylor, T. E.; Newbold, C. I.; Ruebush, T. K.; Danis, M.; Greenwood, B. M.; Anderson, R. M.; Olliaro, P. Averting a malaria disaster. Lancet 1999, 353, 1965-1967.
2. Greenwood, B. M.; Fidock, D. A.; Kyle, D. E.; Kappe, S. H. I.; Alonso, P. L.; Collins, F. H.; Duffy, P. E. Malaria: progress, perils, and prospects for eradication. J. Clin. InVest. 2008, 118, 1266-1276.
3. Tilley, L.; Davis, T. M. E.; Bray, P. G. Prospects for the treatment of drug-resistant malaria parasites. Future Microbiol. 2006, 1, 127-141.
4. Kelly-Hope, L.; Ranson, H.; Hemingway, J. Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. Lancet Infect. Dis. 2008, 8, 387-389.
5. Goldberg, D. E. Plasmodial hemoglobin degradation: an ordered pathway in a specialized organelle. Infect. Agents Dis. 1992, 1, 207- 211.
6. Francis, S. E.; Sullivan, D. J.; Goldberg, D. E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. ReV. Microbiol. 1997, 51, 97-123.
7. Mungthin, M.; Bray, P. G.; Ridley, R. G.; Ward, S. A. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrob. Agents Chemother. 1998, 42, 2973-2977.
8. Bray, P. G.; Mungthin, M.; Ridley, R. G.; Ward, S. A. Access to hematin: the basis of chloroquine resistance. Mol. Pharmacol. 1998, 54, 170-179.
9. O'Neill, P. M.; Bray, P. G.; Hawley, S. R.; Ward, S. A.; Park, B. K. 4-Aminoquinolines. Past, present, and future: a chemical perspective. Pharmacol. Ther. 1998, 77, 29-58.
10. Hawley, S. R.; Bray, P. G.; Mungthin, M.; Atkinson, J. D.; O'Neill, P. M.; Ward, S. A. Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 1998, 42, 682- 686.
11. Bray, P. G.; Martin, R. E.; Tilley, L.; Ward, S. A.; Kirk, K.; Fidock, D. A. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol. Microbiol. 2005, 56, 323-333.
12. Hawley, S. R.; Bray, P. G.; Park, B. K.; Ward, S. A. Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol. Biochem. Parasitol. 1996, 80, 15-25.
13. (a) Neftel, K. A.; Woodtly, W.; Schmid, M.; Frick, P. G.; Fehr, J. Amodiaquine induced agranulocytosis and liver-damage. Br. Med. J. 1986, 292, 721-723.
14. (b) Although there are toxicity concerns with amodiaquine, a new combination of artesunate and amodiaquine (ASAQ) has been launched and amodiaquine continues to be used for uncomplicated malaria in many African countried in combination with sulfadoxine/pyrimethamine.
15. Schulthess, H. K.; von Felten, A.; Gmur, J.; Neftel, K. Amodiaquineinduced agranulocytosis during suppressive treatment of malarias demonstration of an amodiaquine-dependent granulocytotoxic antibody. Schweiz. Med. Wochenschr. 1983, 113, 1912-1913.
16. Maggs, J. L.; Tingle, M. D.; Kitteringham, N. R.; Park, B. K. Drugprotein conjugates. 14. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem. Pharmacol. 1988, 37, 303-311.
17. Maggs, J. L.; Park, B. K. Cyto-toxicity of the quinoneimine of amodiaquine. Br. J. Clin. Pharmacol. 1988, 25, P143.
18. Maggs, J. L.; Colbert, J.; Winstanley, P. A.; Orme, M. L.; Park, B. K. Irreversible binding of amodiaquine to human-liver microsomes: chemical and metabolic factors. Br. J. Clin. Pharmacol. 1987, 23, P649.
19. Harrison, A. C.; Kitteringham, N. R.; Clarke, J. B.; Park, B. K. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 1992, 43, 1421-1430.
20. Rouveix, B.; Coulombel, L.; Aymard, J. P.; Chau, F.; Abel, L. Amodiaquine-induced immune agranulocytosis. Br. J. Clin. Haematol. 1989, 71, 7-11.
21. Clarke, J. B.; Neftel, K.; Kitteringham, N. R.; Park, B. K. Detection of antidrug IgG antibodies in patients with adverse drug-reactions to amodiaquine. Int. Arch. Allergy Appl. Immunol. 1991, 95, 369-375.
22. O'Neill, P. M.; Harrison, A. C.; Storr, R. C.; Hawley, S. R.; Ward, S. A.; Park, B. K. The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. J. Med. Chem. 1994, 37, 1362-1370.
23. O'Neill, P. M.; Mukhtar, A.; Stocks, P. A.; Randle, L. E.; Hindley, S.; Ward, S. A.; Storr, R. C.; Bickley, J. F.; O'Neil, I. A.; Maggs, J. L.; Hughes, R. H.; Winstanley, P. A.; Bray, P. G.; Park, B. K. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J. Med. Chem. 2003, 46, 4933-4945.
24. Lawrence, R. M.; Dennis, K. C.; O'Neill, P. M.; Hahn, D. U.; Roeder, M.; Struppe, C. Development of a scalable synthetic route to GSK369796 (N-tert-butyl isoquine), a novel 4-aminoquinoline antimalarial drug. Org. Process Res. Dev. 2008, 12, 294-297.
25. Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J. X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-based technique for highthroughput antimalarial drug screening. Antimicrob. Agents Chemother. 2004, 48, 1803-1806.
26. Trager, W.; Jenson, J. B. Cultivation of malarial parasites. Nature 1978, 273, 621-622.
27. Stocks, P. A.; Raynes, K. J.; Bray, P. G.; Park, B. K.; O'Neill, P. M.; Ward, S. A. Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum. J. Med. Chem. 2002, 45, 4975-4983.
28. Gemma, S.; Campiani, G.; Butini, S.; Kukreja, G.; Coccone, S. S.; Joshi, B. P.; Persico, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Fattorusso, E.; Taglialatela-Scafati, O.; Savini, L.; Taramelli, D.; Basilico, N.; Parapini, S.; Morace, G.; Yardley, V.; Croft, S.; Coletta, M.; Marini, S.; Fattorusso, C. Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies. J. Med. Chem. 2008, 51, 1278-1294.
29. Peters, W.; Robinson, B. L. Handbook of Animal Models of Infection; Academic Press: San Diego, CA, 1999; pp 757-773.
30. Vippagunta, S. R.; Dorn, A.; Ridley, R. G.; Vennerstrom, J. L. Characterization of chloroquine-hematin mu-oxo dimer binding by isothermal titration calorimetry. Biochim. Biophys. Acta 2000, 1475, 133-140.
31. Dorn, A.; Vippagunta, S. R.; Matile, H.; Jaquet, C.; Vennerstrom, J. L.; Ridley, R. G. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem. Pharmacol. 1998, 55, 727-736.
32. Vippagunta, S. R.; Dorn, A.; Matile, H.; Bhattacharjee, A. K.; Karle, J. M.; Ellis, W. Y.; Ridley, R. G.; Vennerstrom, J. L. Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth. J. Med. Chem. 1999, 42, 4630-4639.
33. Egan, T. J. Haemozoin formation. Mol. Biochem. Parasitol. 2008, 157, 127-136.
34. Egan, T. J. Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation. J. Inorg. Biochem. 2008, 102, 1288-1299.
35. Egan, T. J.; Ncokazi, K. K. Effects of solvent composition and ionic strength on the interaction of quinoline antimalarials with ferriprotoporphyrin IX. J. Inorg. Biochem. 2004, 98, 144-152.
36. Egan, T. J.; Mavuso, W. W.; Ross, D. C.; Marques, H. M. Thermodynamic factors controlling the interaction of quinoline antimalarial drugs with ferriprotoporphyrin IX. J. Inorg. Biochem. 1997, 68, 137-145.
37. Casabianca, L. B.; An, D.; Natarajan, J. K.; Alumasa, J. N.; Roepe, P. D.; Wolf, C.; de Dios, A. C. Quinine and chloroquine differentially perturb heme monomer-dimer equilibrium. Inorg. Chem. 2008, 47, 6077-6081.
38. Parapini, S.; Basilico, N.; Pasini, E.; Egan, T. J.; Olliaro, P.; Taramelli, D.; Monti, D. Standardization of the physicochemical parameters to assess in vitro the beta-hematin inhibitory activity of antimalarial drugs. Exp. Parasitol. 2000, 96, 249-256.
39. Oda, Y.; Funasaka, K.; Kitano, M.; Nakama, A.; Yoshikura, T. Use of a high-throughput umu-microplate test system for rapid detection of genotoxicity produced by mutagenic carcinogens and airborne particulate matter. Environ. Mol. Mutagen. 2004, 43, 10-19.
40. Davis, T. M. E.; Hung, T. Y.; Sim, I. K.; Karunajeewa, H. A.; Ilett, K. F. Piperaquine: a resurgent antimalarial drug. Drugs 2005, 65, 75- 87.
41. Hien, T. T.; Dolecek, C.; Mai, P. P.; Dung, N. T.; Truong, N. T.; Thai, L. H.; An, D. T. H.; Thanh, T. T.; Stepniewska, K.; White, N. J.; Farrar, J. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004, 363, 18-22.
42. Chen, L.; Qu, F.; Zhou, Y. Field observations on the antimalarial piperaquine. Chin. Med. J. 1982, 95, 281-286.
43. Price, R. N.; Hasugian, A. R.; Ratcliff, A.; Siswantoro, H.; Purba, H. L. E.; Kenangalem, E.; Lindegardh, N.; Penttinen, P.; Laihad, F.; Ebsworth, E. P.; Anstey, N. M.; Tjitra, E. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisininpiperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 2007, 51, 4090-4097.
44. Khanh, N. X.; de Vries, P. J.; Ha, L. D.; van Boxtel, C. J.; Koopmans, R.; Kager, P. A. Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for falciparum malaria. Antimicrob. Agents Chemother. 1999, 43, 690-692.
45. Delarue, S.; Girault, S.; Maes, L.; Debreu-Fontaine, M. A.; Labaeid, M.; Grellier, P.; Sergheraert, C. Synthesis and in vitro and in vivo antimalarial activity of new 4-anilinoquinolines. J. Med. Chem. 2001, 44, 2827-2833.
46. Miroshnikova, O. V.; Hudson, T. H.; Gerena, L.; Kyle, D. E.; Lin, A. J. Synthesis and antimalarial activity of new isotebuquine analogues. J. Med. Chem. 2007, 50, 889-896.
47. Casagrande, M.; Basilico, N.; Parapini, S.; Romeo, S.; Taramelli, D.; Sparatore, A. Novel amodiaquine congeners as potent antimalarial agents. Bioorg. Med. Chem. 2008, 16, 6813-6823.
48. Mzayek, F.; Deng, H. Y.; Mather, F. J.; Wasilevich, E. C.; Liu, H. Y.; Hadi, C. M.; Chansolme, D. H.; Murphy, H. A.; Melek, B. H.; Tenaglia, A. N.; Mushatt, D. M.; Dreisbach, A. W.; Lertora, J. J. L.; Krogstad, D. J. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PloS Clin. Trials 2007, 2, e6.
49. Dive, D. Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial. ChemMedChem 2008, 3, 383-391.
50. Warhurst, D. C.; Craig, J. C.; Adagu, P. S.; Guy, R. K.; Madrid, P. B.; Fivelman, Q. L. Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant bloodstages of Plasmodium falciparum: role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases. Biochem. Pharmacol. 2007, 73, 1910-1926.
51. Kuhn, Y.; Rohrbach, P.; Lanzer, M. Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. Cell. Microbiol. 2007, 9, 1004-1013.
52. Pisciotta, J. Neutral lipid microspheres in Plasmodium falciparum digestive vacuoles mediate heme crystallization. Am. J. Trop. Med. Hyg. 2005, 73, 188.
53. Pisciotta, J. M.; Coppens, I.; Tripathi, A. K.; Scholl, P. F.; Shuman, J.; Bajad, S.; Shulaev, V.; Sullivan, D. J., Jr. The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem. J. 2007, 402, 197-204.
54. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual computational chemistry laboratory: design and description. J. Comput.- Aided Mol. Des. 2005, 19, 453-463.
55. Wennerholm, A.; Nordmark, A.; Pihlsgard, M.; Mahindi, M.; Bertilsson, L.; Gustafsson, L. L. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur. J. Clin. Pharmacol. 2006, 62, 539-546.
56. Guguen-Guillouzo, C.; Guillouso, A. Methods for Preparation of Adult and Fetal Hepatocytes. In Research in Isolated and Cultured Hepatocytes; Guillouzo, A., Guguen-Guillouzo, C., Eds.; John Libbey Eurotext/INSERM: London/Paris, 1986; pp 1-12.